Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer

Discover how primary resistance mechanisms impact treatments for multiple myeloma and the role of BCMA-targeted bispecific T-cell engagers. Explore the promising effects of emapalumab therapy on pediatric patients with hemophagocytic lymphohistiocytosis undergoing stem cell transplants. Learn about GSDME-mediated pyroptosis and its connection to increased thrombotic risks in patients receiving cancer chemotherapy. This dynamic discussion uncovers significant advancements in hematological therapies and potential new strategies for improving patient outcomes.